Extensive Stage Small Cell Lung Cancer Clinical Pathology Characteristic And The Correlation Analysis Of PFS

Background and Objective:Lung cancer is the most common malignant tumor in the world.Small cell lung cancer(SCLC)accounts for about 15%-20% of all lung cancers and has its unique natural history,which is mainly related to smoking.Small cell lung cancer(SCLC)is characterized by short tumor cell doubling time,rapid progression,high malignancy,poor prognosis and high recurrence rate.The clinicopathological characteristics and treatment methods of 125 patients with SCLC were retrospectively analyzed,and the factors affecting the progression-free survival of SCLC were analyzed and discussed,so as to provide reference materials for the prediction of efficacy and prognosis of SCLC.Material and Methods:Clinical data of 125 pathologically confirmed patients with primary extensive stage small cell lung cancer admitted to henan cancer hospital from September 13,2012 to February 11,2018 were collected.The survey included: gender,age,KPS score,smoking history,chemotherapy cycle,chemotherapy regimen,treatment method,d-dimer,NSE,CEA,CYFRA211,etc.SPSS21.0 software was used for the statistical analysis of all data.Kaplan-meier method was used for the progression-free survival of all sample data.Log-rank test was used for the survival curves of different groups.Results :The median progression-free survival of SCLC was 6.2 months.Univariate analysis showed that gender,age,smoking history,pre-chemotherapy d-dimer and CEA level were not related to progression-free survival,and KPS score,chemotherapy cycle,treatment,pre-chemotherapy cyfra21-1 and NSE levels were related to progression-free survival(P<0.05).Multivariate analysis showed that chemotherapy cycle was significantly correlated with progression-free survival(P<0.01).Conclusion:Small cell lung cancer patients with low KPS score and high cyfra21-1 and NSE levels before chemotherapy have poor prognosis.The short-term survival time of patients with extensive small-cell lung cancer can be improved by 5-6 cycles of chemotherapy combined with chemoradiotherapy.The number of cycles of chemotherapy is an independent factor affecting the progression-free survival of SCLC.